Overview

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Status:
Completed

Trial end date:
2020-07-15

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/mL) administered by prefilled syringe (PFS) for the treatment of adult participants with moderate to severe plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Antibodies, Monoclonal